Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore how this cancer is affected by a new medication,
cetuximab. Cetuximab is directed towards a protein called EGFR (epidermal growth factor
receptor), that is found in some types of cancer. Studies have shown that this drug can be
beneficial in patients with colon cancer and has been approved by the US Food and Drug
Administration (FDA) for this purpose. The researchers are conducting a study to see if it is
beneficial in patients with sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC